Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.
Most lung adenocarcinoma-associated EGF receptor (EGFR) mutations confer sensitivity to specific EGFR tyrosine kinase inhibitors. The finding that exon 19 insertion mutations are also sensitive to this class of drugs suggests that testing for these mutations should be done and that these patients will benefit from treatment with tyrosine kinase inhibitors.
Yale University School of Medicine, New Haven, CT, USA. katerina.politi@yale.edu
Katerina
K
Politi
Thomas J
TJ
Lynch
D000230:Adenocarcinoma / Q000235:genetics*; D000077192:Adenocarcinoma of Lung; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D008297:Male; D016254:Mutagenesis, Insertional
C512478:EGFR protein, human; D066246:ErbB Receptors